© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#EASL 2017
Community Voices Enrich the International Liver Congress
Click Here for EASL.eu
An Introduction to Hepatitis

EASL 2017 Roundup: Continued Progress in Fighting Liver Disease

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

Older People Who Cleared Hepatitis B Still Have Raised Risk of Liver Cancer

This is particularly true among men older than 50, who warrant greater monitoring.

Curing Hepatitis C Can Get People Off the Liver Transplant List

This holds true even for those with highly severe liver disease.

Merck’s Triple-Drug Hep C Combo Cures Almost All of Retreated Group

The trial tested 16 and 24 weeks of grazoprevir/uprifosbuvir/ruzasvir among those with genotype 1 who had failed a previous treatment.

Treating Liver Cancer With Radioactive Beads Improves Quality of Life

Compared with the standard treatment, this new method also appears to be safer—but it doesn’t offer a longer life.

Generic Versions of Major Hepatitis C Drugs Prove Highly Effective

Some countries, such as Australia and the United Kingdom, permit people to import generic drugs for personal use.

MUST read

Hepatitis C: The Basics
Hepatitis B: The Basics
NASH: The Basics

Gilead’s NASH Drug Shows Promise in Early Trial

A small proof-of-concept study of GS-0976 inhibited de novo lipogenesis (DNL) and reduced liver fat and stiffness.

Reconfigured Version of NASH Drug FGF21 Improves Liver Health

BMS-986036, a retooled version of the non-alcoholic steatohepatitis drug FGF21, showed promise in a Phase II trial.

Liver Fat Isn’t the True Culprit Behind NASH-Related Disease Progression

The actual cause was discovered during the failed trial of a non-alcoholic steatohepatitis (NASH) treatment.

Modified Version of NASH Drug That Was Linked to Cancer Now Shows Promise

Researchers retooled the non-alcoholic steatohepatitis treatment FGF19 to yield a variant dubbed NGM282.

In Those With Cirrhosis, Severe Gum Disease Is Tied With Raised Risk of Death

The risk for death from cirrhosis itself is particularly high.

Hot topics

Forums: Support and discussion
Blogs: The community speaks

Global Viral Hepatitis Death Rate Rivals TB and HIV

A new World Health Organization (WHO) report is the most definitive account to date of the global impact of hepatitis B and C.

Curing Hepatitis Cuts the Risk of Cardiovascular Disease

Among people with hep C and compensated cirrhosis, this risk reduction was particularly stark after six years of follow-up.

Janssen/Achillion’s Triple-Drug Hep C Regimen Cures All Those With Genotype 1

The joint venture between the two companies will push the three-drug Olysio/odalasvir/AL-335 into further development.

Eight Weeks of AbbVie’s G/P Cures Almost All Those With Genotype 3 of Hep C

The investigational glecaprevir/pibrentasvir was tested among people with genotype 3 of hepatitis C virus who did not have cirrhosis.

Excellent Hepatitis C Cure Rates for Zepatier Among Veterans

Real-world data showed Merck’s hep C regimen performed well among a population with genotypes 1 or 4 and multiple other health conditions.
Advertisement
Treatment News
Newsfeed
Features
Ask Hep